Legacy Financial Advisors Inc. Decreases Holdings in Pfizer Inc. (NYSE:PFE)

Legacy Financial Advisors Inc. cut its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 22.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 40,436 shares of the biopharmaceutical company's stock after selling 11,757 shares during the quarter. Legacy Financial Advisors Inc.'s holdings in Pfizer were worth $1,073,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of PFE. Nordea Investment Management AB lifted its holdings in shares of Pfizer by 36.1% in the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock worth $108,002,000 after acquiring an additional 1,080,822 shares during the last quarter. Parsons Capital Management Inc. RI lifted its stake in Pfizer by 118.7% during the fourth quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock worth $7,820,000 after purchasing an additional 159,984 shares in the last quarter. Copley Financial Group Inc. purchased a new position in shares of Pfizer during the third quarter worth $577,000. Mcdonald Partners LLC grew its stake in shares of Pfizer by 9.9% in the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock valued at $2,926,000 after buying an additional 9,963 shares in the last quarter. Finally, Merit Financial Group LLC raised its holdings in shares of Pfizer by 60.8% in the 4th quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company's stock valued at $3,395,000 after buying an additional 48,397 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Pfizer Stock Performance

Pfizer stock traded up $0.14 during midday trading on Monday, hitting $22.05. 26,674,615 shares of the company's stock were exchanged, compared to its average volume of 40,187,113. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a market cap of $125.06 billion, a price-to-earnings ratio of 15.64, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The firm's 50 day simple moving average is $25.25 and its 200 day simple moving average is $26.38.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm's revenue was up 24.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.10 EPS. Equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.06% of the company's stock.

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent research reports. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. Finally, Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $31.07.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.